Search clinical trials for: Pexastimogene Devacirepvec (Pexa-Vec)

Total 95 results

National Cancer Institute (NCI)

Completed

A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

Colorectal Neoplasms | Colorectal Cancer | Colorectal Carcinoma | Colorectal Adenocarcinoma | Refractory Cancer

United States
Lee's Pharmaceutical Limited

Recruiting

Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma

Local Progression or Metastatic Melanoma With Failed First-line Treatment

China
Jennerex Biotherapeutics

Completed

A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma

Melanoma

United States
SillaJen, Inc.
Regeneron Pharmaceuticals

Active, not recruiting

A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma

Renal Cell Carcinoma

United States, Australia, Korea, Republic of
Transgene

Terminated

A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma (HCC)

France
Jennerex Biotherapeutics

Completed

A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer (FLASH)

Hepatocellular Carinoma

United States, Korea, Republic of, Spain
SillaJen, Inc.

Completed

Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone (PHOCUS)

Hepatocellular Carcinoma (HCC)

United States, Canada, New Zealand, Australia, China, France, Germany, Hong Kong, Israel, Italy, Korea, Republic of, Portugal, Singapore, Taiwan, Thailand, United Kingdom
Jennerex Biotherapeutics

Terminated

Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors

Colorectal Carcinoma

Canada
Jennerex Biotherapeutics
Solving Kids' Cancer

Completed

Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients

Lymphoma | Neuroblastoma | Rhabdomyosarcoma | Wilm's Tumor | Ewing's Sarcoma

United States
Centre Leon Berard
Transgene

Completed

Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. (ISI-JX)

Advanced Tumor | Metastatic Tumor

France
Jennerex Biotherapeutics
Samsung Medical Center

Completed

Safety Study of Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma

Carcinoma, Colorectal

Korea, Republic of
Vanda Pharmaceuticals

Completed

VEC-162 Study in Adult Patients With Primary Insomnia

Primary Insomnia

United States
Jennerex Biotherapeutics
Green Cross Corporation

Completed

A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma

Neoplasms, Liver

Korea, Republic of
Lund University Hospital

Recruiting

Exhaled Breath Particles in Lung Cancer

Lung Cancer | Lung Adenocarcinoma | Non-small Cell Lung Cancer | Squamous Cell Lung Cancer

Sweden
The Netherlands Cancer Institute
Amgen

Active, not recruiting

Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB/C/D-IV M1a) Melanoma With Injectable Disease (NIVEC)

Melanoma Stage IV | Melanoma Stage III

Netherlands
Vanda Pharmaceuticals

Completed

VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia

Insomnia

United States
University of Zurich

Completed

T-VEC in Non-melanoma Skin Cancer (20139157 T-VEC)

Merkel Cell Carcinoma | Basal Cell Carcinoma | Squamous Cell Carcinoma | Non-melanoma Skin Cancer | Cutaneous Lymphoma

Switzerland
Jennerex Biotherapeutics

Completed

A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Korea, Republic of
Jennerex Biotherapeutics

Completed

A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma

Carcinoma, Hepatocellular

United States, Korea, Republic of, Canada
Vanda Pharmaceuticals

Completed

Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers

Circadian Rhythm Sleep Disorders

United States
Sameer Avasarala

Recruiting

LUng voluMe reductIoN by DuAl ENergy CT Evaluation (LUMINANCE) Study

Lung Perfusion

United States
Vanda Pharmaceuticals

Completed

Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder

Non-24-Hour Sleep-Wake Disorder

United States, Germany
Guangzhou Sinogen Pharmaceutical Co., Ltd
Parexel

Recruiting

Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China, Taiwan
Guangzhou Sinogen Pharmaceutical Co., Ltd
Parexel; ClinChoice Enterprise Management (Shanghai) Limited

Recruiting

Study of SGN1 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

United States, China
Vanda Pharmaceuticals

Active, not recruiting

Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception

Non 24 Hour Sleep Wake Disorder

France
Vanda Pharmaceuticals

Completed

Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

Non-24-Hour Sleep-Wake Disorder

United States
Vanda Pharmaceuticals

Completed

Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function

Renal Impairment

United States
Vanda Pharmaceuticals

Completed

Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder

Non-24-Hour Sleep-Wake Disorder

United States
Vecmedical Spain, S.L.

Recruiting

Rectal Tumor Resection Using the UNI-VEC Multichannel Transanal Access Device (UNI-VEC)

Rectal Polyp | Rectal Lesion | Sessile Colonic Polyp | Rectal Polyps | Pedunculated Colorectal Polyps

Spain
Jennerex Biotherapeutics

Completed

Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors

Melanoma | Renal Cell Carcinoma | Lung Cancer | Squamous Cell Carcinoma of the Head and Neck

United States, Canada
SOLTI Breast Cancer Research Group
Roche Pharma AG; Amgen

Active, not recruiting

Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer (PROMETEO)

Breast Cancer

Spain
Chengdu Kanghong Biotech Co., Ltd.
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Recruiting

A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma

Retinoblastoma

China
Vanda Pharmaceuticals

Completed

Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy Subjects

Healthy Volunteers

United States
Krystal Biotech, Inc.

Completed

A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa

Dystrophic Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa | Dominant Dystrophic Epidermolysis Bullosa | DEB - Dystrophic Epidermolysis Bullosa

United States
Karie D. Runcie, MD
Amgen

Active, not recruiting

Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer

Pancreatic Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute

Terminated

Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma

Angiosarcoma of Skin

United States
Memorial Sloan Kettering Cancer Center
Amgen

Completed

A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

Melanoma | Merkel Cell Carcinoma | Other Solid Tumors

United States
Vanda Pharmaceuticals

Completed

Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.

Healthy

United States
Institut Bergonié
Merck Sharp & Dohme LLC; National Cancer Institute, France; Transgene; Fondation...

Recruiting

A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) (METROmaJX)

Breast Cancer | Soft-tissue Sarcoma | Solid Tumors

France
Vanda Pharmaceuticals

Completed

Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment

Hepatic Impairment

United States
University of California, Davis
Amgen

Suspended

Neoadjuvant T-VEC in High Risk Early Melanoma

Melanoma

United States
Jennerex Biotherapeutics
Transgene

Completed

Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma

Colorectal Carcinoma | CRC

Canada, United States, France
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC; Amgen

Active, not recruiting

A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Sarcoma | Epithelioid Sarcoma | Cutaneous Angiosarcoma

United States
Royal Marsden NHS Foundation Trust

Completed

TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion) (TITAN)

Melanoma and Sarcoma

United Kingdom
Chen Xiaoping

Recruiting

Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma

HCC

China
Dan Blazer III, M.D.

Completed

Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO)

Stage IV Peritoneal Surface Dissemination From Gastrointestinal or Recurrent, Platinum-resistant Ovarian Cancer That Cannot be Completely Resected

United States
Amgen

Completed

Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma

Unresectable Stage IIIB-IV Malignant Melanoma

Japan
Hvidovre University Hospital

Active, not recruiting

Breastfeeding Duration and Tongue-tie in Neonates.

Infant Nutrition Disorders

Denmark
Virginia Eye Consultants

Unknown

An Open Label Comparing the Short Term Efficacy of Lacrisert

Dry Eye

United States
Amgen

Completed

Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma (TVEC-325)

Unresected Stage IIIb to IVM1c Melanoma

France, Poland, Italy, Russian Federation, Netherlands, Spain, United States, Austria, Belgium, United Kingdom, Germany, Hungary, Greece

Search clinical trials for: Pexastimogene Devacirepvec (Pexa-Vec)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations